Quarterly report · Q1
9987.TEDINET S100RMWL
Period2023-04-01 → 2023-06-30
Filed2023-08-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥573.6bn | 2023-04-01 → 2023-06-30 | Cons. | Net sales |
| Revenue | ¥2.31T | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥553.8bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Operating income | ¥4.1bn | 2023-04-01 → 2023-06-30 | Cons. | Operating income |
| Operating income | ¥3.5bn | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Ordinary income | ¥5.0bn | 2023-04-01 → 2023-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥36.4bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.6bn | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥5.1bn | 2023-04-01 → 2023-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥4.5bn | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥3.3bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥20.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.7bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥3.3bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss |
| Net income | ¥2.7bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Total assets | ¥1.19T | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥1.15T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.17T | at 2022-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥772.0bn | at 2023-06-30 | Cons. | Liabilities |
| Total liabilities | ¥734.6bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥418.1bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥411.5bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥419.3bn | at 2022-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥114.2bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥109.0bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥40.4 | 2023-04-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥236.47 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥30.49 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 35.1% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.0% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 40
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q1r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥23.9bn |
| jpcrp040300-q1r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥23.9bn |
| jpcrp040300-q1r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥3m |
| jpcrp040300-q1r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | −¥38m |
| jpcrp040300-q1r_E02780-000The Healthcare Product Development Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥12.8bn |
| jpcrp040300-q1r_E02780-000The Healthcare Product Development Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥2.9bn |
| jpcrp040300-q1r_E02780-000The Healthcare Product Development Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥9.9bn |
| jpcrp040300-q1r_E02780-000The Healthcare Product Development Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥521m |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥63.8bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥7.1bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥56.7bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥213m |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥553.4bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥539.8bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥13.7bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥3.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-06-30 | ¥653.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-06-30 | ¥573.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥80.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-06-30 | ¥4.0bn |
| jpcrp040300-q1r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥24.0bn |
| jpcrp040300-q1r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥24.0bn |
| jpcrp040300-q1r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥0 |
| jpcrp040300-q1r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥198m |
| jpcrp040300-q1r_E02780-000The Healthcare Product Development Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥11.8bn |
| jpcrp040300-q1r_E02780-000The Healthcare Product Development Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥3.2bn |
| jpcrp040300-q1r_E02780-000The Healthcare Product Development Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥8.6bn |
| jpcrp040300-q1r_E02780-000The Healthcare Product Development Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥613m |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥49.7bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥6.9bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥42.7bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥242m |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥533.5bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥519.6bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥13.8bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥2.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-06-30 | ¥618.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-06-30 | ¥553.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥65.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-06-30 | ¥3.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 344
| Item | Context | Value | Unit |
|---|---|---|---|
| Provision for loss on anti monopoly act cl | CurrentQuarterInstant | 9790000000 | JPY |
| Other cl | Prior1YearInstant | 19388000000 | JPY |
| Other cl | CurrentQuarterInstant | 41938000000 | JPY |
| Current liabilities | Prior1YearInstant | 711274000000 | JPY |
| Current liabilities | CurrentQuarterInstant | 745979000000 | JPY |
| Net defined benefit liability | Prior1YearInstant | 2323000000 | JPY |
| Net defined benefit liability | CurrentQuarterInstant | 2300000000 | JPY |
| Other ncl | Prior1YearInstant | 20973000000 | JPY |
| Other ncl | CurrentQuarterInstant | 23729000000 | JPY |
| Noncurrent liabilities | Prior1YearInstant | 23297000000 | JPY |
| Noncurrent liabilities | CurrentQuarterInstant | 26030000000 | JPY |
| Liabilities | Prior1YearInstant | 734571000000 | JPY |
| Liabilities | CurrentQuarterInstant | 772009000000 | JPY |
| Capital stock | Prior1YearInstant | 13546000000 | JPY |
| Capital stock | CurrentQuarterInstant | 13546000000 | JPY |
| Capital surplus | Prior1YearInstant | 32452000000 | JPY |
| Capital surplus | CurrentQuarterInstant | 32452000000 | JPY |
| Retained earnings | Prior1YearInstant | 334694000000 | JPY |
| Retained earnings | CurrentQuarterInstant | 335103000000 | JPY |
| Treasury stock | Prior1YearInstant | -371000000 | JPY |
| Treasury stock | CurrentQuarterInstant | -371000000 | JPY |
| Shareholders equity | Prior1YearInstant | 380321000000 | JPY |
| Shareholders equity | CurrentQuarterInstant | 380729000000 | JPY |
| Valuation difference on available for sale securities | Prior1YearInstant | 33330000000 | JPY |
| Valuation difference on available for sale securities | CurrentQuarterInstant | 39554000000 | JPY |
| Revaluation reserve for land | Prior1YearInstant | -4724000000 | JPY |
| Revaluation reserve for land | CurrentQuarterInstant | -4769000000 | JPY |
| Foreign currency translation adjustment | Prior1YearInstant | 1349000000 | JPY |
| Foreign currency translation adjustment | CurrentQuarterInstant | 1347000000 | JPY |
| Remeasurements of defined benefit plans | Prior1YearInstant | 932000000 | JPY |
| Remeasurements of defined benefit plans | CurrentQuarterInstant | 881000000 | JPY |
| Valuation and translation adjustments | Prior1YearInstant | 30887000000 | JPY |
| Valuation and translation adjustments | CurrentQuarterInstant | 37014000000 | JPY |
| Non controlling interests | Prior1YearInstant | 316000000 | JPY |
| Non controlling interests | CurrentQuarterInstant | 309000000 | JPY |
| Net assets | Prior1YearInstant | 411525000000 | JPY |
| Net assets | CurrentQuarterInstant | 418053000000 | JPY |
| Liabilities and net assets | Prior1YearInstant | 1146097000000 | JPY |
| Liabilities and net assets | CurrentQuarterInstant | 1190063000000 | JPY |
| Net sales | Prior1YTDDuration | 553754000000 | JPY |
| Net sales | CurrentYTDDuration | 573644000000 | JPY |
| Cost of sales | Prior1YTDDuration | 514816000000 | JPY |
| Cost of sales | CurrentYTDDuration | 533007000000 | JPY |
| Gross profit | Prior1YTDDuration | 38937000000 | JPY |
| Gross profit | CurrentYTDDuration | 40637000000 | JPY |
| Selling general and administrative expenses | Prior1YTDDuration | 35387000000 | JPY |
| Selling general and administrative expenses | CurrentYTDDuration | 36581000000 | JPY |
| Operating income | Prior1YTDDuration | 3550000000 | JPY |
| Operating income | CurrentYTDDuration | 4055000000 | JPY |
| Interest income noi | Prior1YTDDuration | 28000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |